Free Trial
NASDAQ:PYPD

PolyPid Q4 2023 Earnings Report

PolyPid logo
$3.41 +0.05 (+1.49%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$3.40 -0.01 (-0.15%)
As of 08/1/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PolyPid EPS Results

Actual EPS
-$3.97
Consensus EPS
-$2.17
Beat/Miss
Missed by -$1.80
One Year Ago EPS
N/A

PolyPid Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PolyPid Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

PolyPid's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

PolyPid Earnings Headlines

One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas.
See More PolyPid Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PolyPid? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PolyPid and other key companies, straight to your email.

About PolyPid

PolyPid (NASDAQ:PYPD), a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

View PolyPid Profile

More Earnings Resources from MarketBeat